Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer

Annals of Oncology

Volumn 23, Issue 10, 2012, Pages 2638-2642

  Ajani, J A ^a   Correa, A M ^a   Hofstetter, W L ^a   Rice, D C ^a   Blum, M A ^a   Suzuki, A ^a   Taketa, T ^a   Welsh, J ^a   Lin, S H ^a   Lee, J H ^a   Bhutani, M S ^a   Ross, W A ^a   Maru, D M ^a   Macapinlac, H A ^a   Erasmus, J ^a   Komaki, R ^a   Mehran, R J ^a   Vaporciyan, A A ^a   Swisher, S G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chemoradiation; Esophageal cancer; Esophageal preservation; Nomogram; Prediction of response

Indexed keywords

FLUOROPYRIMIDINE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL FEATURE; DISEASE FREE SURVIVAL; DRUG RESPONSE; ENDOSCOPIC BIOPSY; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LOGISTIC REGRESSION ANALYSIS; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; NOMOGRAM; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE CARE; PREDICTION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL;

COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; HUMANS; MULTIVARIATE ANALYSIS; SURVIVAL ANALYSIS;

EID: 84867130488     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds210     Document Type: Article

References (32)

1. Parkin DM, Bray F, Ferlay J et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55(2): 74-108.
2. Ferlay J, Shin HR, Bray F et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010.
3. Cancer Research UK. Oesophageal (gullet) cancer. [on-line] 2008; http://info.cancerresearchuk.org/cancerstats/types/oesophagus/incidence/ (14 October 2008, date last accessed).
4. Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst 2008; 100(16): 1184-1187.
5. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005; 97 (2): 142-146.
6. Rice TW, Rusch VW, Apperson-Hansen C et al. Worldwide esophageal cancer collaboration. Dis Esophagus 2009; 22(1): 1-8.
7. Gaast AV, Van Hagen P, Hulshof M et al. Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer. Results from a multicenter randomized phase III study. Am Soc Clin Oncol 2010: 5s.
8. Ajani JA. Resectable esophageal cancer: surgery as primary therapy is not the answer, but then, what is and why? J Clin Oncol 2010.
9. Allum WH, Stenning SP, Bancewicz J et al. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 2009; 27(30): 5062-5067.
10. Kelsen DP, Winter KA, Gunderson LL et al. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol 2007; 25(24): 3719-3725.
11. Rohatgi P, Swisher SG, Correa AM et al. Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response. Cancer 2005; 104(11): 2365-2372.
12. Chirieac LR, Swisher SG, Ajani JA et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer 2005; 103(7): 1347-1355.
13. Berger AC, Farma J, Scott WJ et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 2005; 23(19): 4330-4337.
14. Rizk NP, Venkatraman E, Bains MS et al. American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma. J Clin Oncol 2007; 25(5): 507-512.
15. Donahue JM, Nichols FC, Li Z et al. Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival. Ann Thorac Surg 2009; 87(2): 392-398; discussion 398- 399.
16. Rohatgi PR, Swisher SG, Correa AM et al. Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus. Cancer 2005; 104(7): 1349-1355.
17. Murthy SB, Patnana SV, Xiao L et al. The standardized uptake value of 18-fluoro-deoxy glucose positron emission tomography after chemoradiation and clinical outcome in patients with localized gastroesophageal carcinoma. Oncology 2010; 78(5-6): 316-322.
18. Flamen P, Van Cutsem E, Lerut A et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 2002; 13(3): 361-368.
19. Swisher SG, Erasmus J, Maish M et al. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer 2004; 101(8): 1776-1785.
20. Wieder HA, Ott K, Lordick F et al. Prediction of tumor response by FDG-PET: comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction. Eur J Nucl Med Mol Imaging 2007; 34(12): 1925-1932.
21. Weber WA, Ott K, Becker K et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001; 19(12): 3058-3065.
22. Izzo JG, Malhotra U, Wu TT et al. Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma. J Clin Oncol 2006; 24(5): 748-754.
23. Luthra R, Wu TT, Luthra MG et al. Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation. J Clin Oncol 2006; 24(2): 259-267.
24. Wu TT, Chirieac LR, Abraham SC et al. Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a reliable predictor for patient outcome. Am J Surg Pathol 2007; 31(1): 58-64.
25. Greene FL. AJCC Cancer Staging Atlas/American Joint Committee on Cancer. New York, NY: Springer 2006.
26. Ajani JA, Correa AM, Walsh GL et al. Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junction. Cancer 2010; 116(7): 1656-1663. doi:10.1002/cncr.24935
27. Javeri H, Arora R, Correa AM et al. Influence of induction chemotherapy and class of cytotoxics on pathologic response and survival after preoperative chemoradiation in patients with carcinoma of the esophagus. Cancer 2008; 113 (6): 1302-1308.
28. Javeri H, Xiao L, Rohren E et al. The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma. Cancer 2009; 115(22): 5184-5192.
29. Bolton WD, Hofstetter WL, Francis AM et al. Impact of tumor length on longterm survival of pT1 esophageal adenocarcinoma. J Thorac Cardiovasc Surg 2009; 138(4): 831-836.
30. Patel PR, Yao JC, Hess K et al. Effect of timing of metastasis/disease recurrence and histologic differentiation on survival of patients with advanced gastric cancer. Cancer 2007; 110(10): 2186-2190.
31. Murthy SB, Patnana SV, Xiao L et al. The standardized uptake value of 18-fluorodeoxyglucose positron emission tomography after chemoradiation and clinical outcome in patients with localized gastroesophageal carcinoma. Oncology; 78(5-6): 316-322.
32. Yang Q, Cleary KR, Yao JC et al. Significance of post-chemoradiation biopsy in predicting residual esophageal carcinoma in the surgical specimen. Dis Esophagus 2004; 17(1): 38-43.